FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

FONAR CorporationNASDAQ: FONR

Revenue · Q3 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q3 FY2026 revenue of $26.47M fell 2.6% year over year, behind the +2.3% change in trailing-twelve-month revenue. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.6% toward the trailing-twelve-month pace of +2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.47M+3.6% QoQ
Last fiscal yearJun 2025
$104.35M+1.4% YoY
LTMMar 2026
$105.34M+2.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.6%——
1 year+1.4%——
3-year CAGR+2.3%——
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
104.35M USD
Year-over-year change
+1.4%
4-year CAGR
+3.8%

Revenue vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +2.3% is the 3rd highest of 6, against a peer median of +1.2%.
  • Over three fiscal years its annual growth of +2.3% compares with a peer median of +22.4%.
FONR Competitors
Revenue for FONR and competitors
Company Period LTM YoY 3-year CAGR
FONRFONAR CorporationLTM Mar 2026$105.34M USD+2.3%+2.3%
LUNGPulmonx CorporationLTM Mar 2026$88.55M USD+1.2%+19.0%
RCELAVITA Medical, Inc.LTM Mar 2026$72.35M USD+1.0%+27.7%
APYXApyx Medical CorporationLTM Mar 2026$55.9M USD+18.2%+5.9%
HYPRHyperfine, Inc.LTM Mar 2026$15.33M USD+30.7%+25.8%
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD——
VANIVivani Medical, Inc.LTM Mar 2026$0 USD——
Peer median (excluding FONR) —+1.2%+22.4%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.